Yifan Pharmaceutical obtained a drug registration certificate

Zhitong
2025.09.16 09:19
portai
I'm PortAI, I can summarize articles.

According to the Zhitong Finance APP, Yifan Pharmaceutical announced that its wholly-owned subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. received the Drug Registration Certificate for injectable isavuconazole issued by the National Medical Products Administration on September 15, 2025. Injectable isavuconazole is an anti-infective drug indicated for the treatment of the following infections in adult patients: invasive aspergillosis and invasive mucormycosis

According to the Zhitong Finance APP, Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. received the Drug Registration Certificate for injectable isavuconazole issued by the National Medical Products Administration on September 15, 2025. Injectable isavuconazole is an anti-infective drug indicated for the treatment of the following infections in adult patients: invasive aspergillosis and invasive mucormycosis

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer